Labiotech.eu

News and Trends 17 Sep 2015

Forbion’s Dutch biotech draws Cali’s Amgen into €1.36Bn deal

Californian Amgen has announced its plans to acquire the Dutch pharma Dezima off of Forbion for €265M upfront. An additional €1.1Bn will be paid through development on their cardiovascular drug candidate which has shown good results in its phase II trial. Amgen is set to buy out Forbion’s portfolio of Amsterdam based Dezima Pharma, a […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

This new Bioplastic plant integrates breakthrough Biotech innovations

Bioplastics hasn’t replaced plastics yet. One new milestone has now been reached, the French company Carbios has just opened its pilot plant to produce biodegradable plastics thanks to its breakthrough enzyme-based technology. Whilst various green initiatives push for better regulation of recycling (a prime example being in Berlin!), in reality only around 10% of plastic […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

Welcome to the Golden age for Gene Editing!

Nuclease-based gene editing technology has opened up how biotechs approach genomic research in industry. A review by Boston Consulting Group explores the background to this excitingly complex field, highlighting how the lengthy genetic revolution has been leading up to this point. Boston Consulting Group has released a report on the importance of gene editing to […]

September 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 16 Sep 2015

Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments

Gene Editing has been made much easier thanks to CRISPR but managing your genome editing workflow can be a challenge. London-based Desktop Genetics wants to solve this problem and just raised additional funding to accelerate its development. CRISPR is already considered as the biotech revolution of this century. Having an easy tool is one thing, but being […]

September 16, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Sep 2015

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle type 2 diabetes when both oral medication fails and basal insulin loses its efficacy. Lixisenatide (Lyxumia outside the US) was initially discovered by Zealand […]

September 16, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Sep 2015

Will bacteriophages solve the antibiotic resistance problem in the EU?

French Pherecydes Pharma has launched the first EU clinical bacteriophage phase I/II trial to fight hospital acquired infections (HAIs) in military hospitals and burn units. In collaboration with two other French biotechs, the Phagoburn project aims to combat the stigma against human bacteriophage therapies in the EU and US in order to battle the oncoming […]

September 15, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 15 Sep 2015

Louvain-la-Neuve: A Belgian temple for success in cell therapy

Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step closer to reality after successfully closing a €28M Series A round. The spin-off of Université Catholique de Louvain coexists with Celyad and Promethera in a biotech cluster where cell therapy is the key protagonist. The financing round, led by New […]

September 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Sep 2015

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Update 22/10/2015: I added Galapagos from Belgium and Basilea from Switzerland, they deserved it … Talking about billon-dollar companies in the US is such a hype. Even the Wall street journal has its own start-up club (which btw is stunning). By looking at it, I wondered which European Biotechs were worth over €1Bn in Europe. […]

September 15, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 14 Sep 2015

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

TxCell, from Nice (Fr), has been granted EU and US Orphan Drug Designation for its T-cell based therapy for autoimmune uveitis – an eye inflammatory disease responsible of 10-15% legal blindness in developed countries. TxCell is a spin-off from France’s National Institute for Health and Medical Research (Inserm), with a pipeline including a phase II […]

September 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

Market holds their breath with whispers of €2.2BN hyperkalemia offer from Actelion

ZS Pharma shares shot up by 30% in value this week due to Swiss big-pharma Actelion admitting it might be interested in buying out the biotech for €2.2BN. This comes as ZS Pharma’s hyperkalemia candidate is set to receive FDA approval for May 2016, although this acquisition rumour could be premature given competitor Relypsa is […]

September 14, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

64 million infected: A brief overview of ReViral and its RSV vaccine competition

Respiratory Syncytial Virus (RSV) affects millions annually, therefore attracting many large biotechs to research a vaccine. ReViral (London, UK) has secured €18.5M series A investment into its pre-clinical pipeline. VC investors Edmond de Rothschild, OrbiMed and Brace Pharma Capital back this award winning antiviral program, despite an array of competitors. ReViral have got the go […]

September 14, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

High-Throughput screening of drug candidates made easier by FRETinFLOW

A multidisciplinary team from France has come up with a robust approach to detect molecular interactions in a reliable way using flow cytometry. This technology could lead to the discovery of new drugs via High-Throughput screening. Flow cytometry is a laser-based, biophysical technology employed by scientists all over the world to count and sort cells. It does this by […]

September 14, 2015 - 4 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Forbion’s Dutch biotech draws Cali’s Amgen into €1.36Bn deal

This new Bioplastic plant integrates breakthrough Biotech innovations

Welcome to the Golden age for Gene Editing!

Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Will bacteriophages solve the antibiotic resistance problem in the EU?

Louvain-la-Neuve: A Belgian temple for success in cell therapy

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

Market holds their breath with whispers of €2.2BN hyperkalemia offer from Actelion

64 million infected: A brief overview of ReViral and its RSV vaccine competition

High-Throughput screening of drug candidates made easier by FRETinFLOW

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!